In in­sulin re­sis­tance pact, Dew­point adds No­vo Nordisk to its phar­ma-rich pipeline

Dew­point Ther­a­peu­tics has lined up an­oth­er Big Phar­ma part­ner, this time Dan­ish drug­mak­er No­vo Nordisk, in a bet that its strat­e­gy of go­ing af­ter mol­e­c­u­lar clus­ters known as con­den­sates could have an im­pact on in­sulin re­sis­tance and di­a­bet­ic com­pli­ca­tions.

The deal in­cludes $55 mil­lion in the near-term from No­vo, plus as much as $690 mil­lion in clin­i­cal, com­mer­cial and sales mile­stones, on top of roy­al­ties, for two po­ten­tial prod­ucts, the com­pa­nies said Wednes­day. The Dan­ish part­ner can al­so look at non-small mol­e­cule drugs, which would trig­ger up to $107.5 mil­lion in mile­stones for each of those prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER